This project is one of six projects supported through the 2026 Advancing Groundbreaking Research in Alzheimer’s and Parkinson’s Diseases – Team Award. Meet the research team members.
This funding opportunity is made possible by the Canada Brain Research Fund (CBRF), an innovative arrangement between the Government of Canada (through Health Canada) and the Brain Canada Foundation, in partnership with the Alzheimer Society of BC and Yukon, Branch Out Neurological Foundation, CLEAR Foundation, Health Research BC, Pacific Parkinson’s Research Institute, Parkinson Society BC, and the Patrick & Dulcie Lenox Endowment.
Project summary
This BC-based project is led by the University of British Columbia. It includes international collaboration and uses samples and data from a large international Parkinson’s disease study. Parkinson’s disease is often diagnosed only after movement problems appear. By then, some permanent damage to brain cells may have already occurred. There is no reliable blood test that can detect the disease early or show how it is changing over time. Some people have rapid eye movement sleep behaviour disorder, which can cause movement or talking during dreams. Many later develop Parkinson’s disease or a related condition, so this group may offer an important opportunity for earlier detection.
Our team will study extracellular vesicles, tiny particles in the blood that carry proteins and other biological information. Our early findings suggest that vesicles linked to red blood cells contain higher levels of a protein called alpha-1 antichymotrypsin, or ACT, in people with Parkinson’s disease. Higher ACT levels also appear to be related to more severe symptoms.
We will test whether this marker can track disease progression, develop a practical blood test, and study whether lowering ACT reduces Parkinson’s-related changes in laboratory models. We will also look for blood markers that may help identify people with sleep behaviour disorder who are at greater risk.
People with lived experience will help guide the project through advisory meetings and workshops. They will provide input on research priorities, study design, interpretation of results, and how sensitive information about disease risk should be communicated. They will also help prepare public summaries, educational materials, webinars, and outreach activities.
The project may support earlier and more objective monitoring, improve clinical trial design, and open new directions for treatment research. It will also train three doctoral students in biomarker research, diagnostic development, data analysis, drug delivery, and patient-oriented research.
Keywords: Parkinson’s disease; rapid eye movement sleep behaviour disorder; extracellular vesicles; blood-based biomarkers; early detection; disease monitoring; patient-oriented research
Team members
Role: Principal Investigator
Department: Department of Medicine
Position: Tong Louie Chair Professor in Pharmaceutical Sciences
Silke Appel-Cresswell
Role: Co-Lead
Department: Medicine/Neurology
Position: Marg Meikle Associate Professor in Parkinson’s Research
Lucas Zhang
Role: Trainee
Department: Faculty of Pharmaceutical Sciences
Position: PhD Student
Russ Algar
Role: Co-Lead
Department: Faculty of Chemistry
Position: Professor
Hao-Yuan Hung
Role: Co-Lead
Department: Faculty of Pharmaceutical Sciences
Position: Visiting Professor
Sam Fereshtehnejad
Role: Co-Lead
Department: Pacific Parkinson’s Research Centre
Position: Assistant Professor
Sherry Wu
Role: Trainee
Department: Faculty of Chemistry
Position: PhD Candidate
Letong Wang
Role: Trainee
Department: Faculty of Pharmaceutical Sciences
Position: PhD Student
Role: Co-Lead
Department: Faculty of Pharmaceutical Sciences
Position: Associate Professor and Canada Research Chair
Role: Co-Lead
Department: Faculty of Pharmaceutical Sciences
Position: Associate Professor and Canada Research Chair In Open Science and Epidemiology








